Natco Pharma share price rose 9 percent in the early trade on March 8 after the company launched the first generic version of Revlimid in the US market.
"Natco Pharma Limited, along with its marketing partner Arrow International Ltd (an affiliate of Teva Pharmaceutical Industries Ltd), announced launch of the first generic version of Revlimid (Lenalidomide capsules) in 5mg, l0mg, l5mg, and 25mg strengths in the US market," company said in its release.
The above strengths of lenalidomide capsules are prescribed in adults for the treatment of (1) multiple myeloma in combination with the medicine dexamethasone, (2) certain myelodysplastic syndromes, and (3) mantle cell lymphoma following specific prior treatment.
Catch all the market action on our live blog
Natco and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene (now part of Bristol-Myers Squibb).
At 9:19am, Natco Pharma was quoting at Rs 883, up Rs 38.70, or 4.58 percent on the BSE.
The share touched a 52-week high of Rs 1,188.95 and a 52-week low of Rs 750.45 on May 24, 2021 and February 24, 2022, respectively. It is trading 25.73 percent below its 52-week high and 17.66 percent above its 52-week low.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
